Prime Medicine, Inc. (PRME)
NASDAQ:PRME
US Market
Holding PRME?
Track your performance easily

Prime Medicine, Inc. (PRME) Income Statement

541 Followers

Prime Medicine, Inc. Income Statement

Last quarter (Q2 2024), Prime Medicine, Inc.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Prime Medicine, Inc.'s net income was $-55.33M. See Prime Medicine, Inc.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 759.00K$ 168.00K-$ 0.00$ 5.21M
Cost of Revenue
-----
Gross Profit
$ 759.00K$ 168.00K---
Operating Expense
$ 224.11M$ 204.79M$ -116.54M$ 84.47M$ 6.14M
Operating Income
$ -223.51M$ -204.79M$ -116.54M$ -84.47M$ -932.00K
Net Non Operating Interest Income Expense
$ 2.31M-$ -8.13M--
Other Income Expense
$ -2.93M$ -7.12M$ -1.90M$ -81.38M$ -611.00K
Pretax Income
$ -224.39M$ -198.41M$ -122.77M$ -165.85M$ -1.54M
Tax Provision
$ -108.00K$ -279.00K$ -948.00K$ -486.00K$ 1.87M
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -217.44M$ -198.13M$ -284.03M$ -184.12M$ -5.05M
Basic EPS
$ -2.16$ -2.18$ -4.19$ -2.55$ -0.07
Diluted EPS
$ -2.16$ -2.18$ -4.19$ -2.55$ -0.07
Basic Average Shares
$ 408.00M$ 90.97M$ 33.89M$ 64.90M$ 71.80M
Diluted Average Shares
$ 408.00M$ 90.97M$ 33.89M$ 64.90M$ 71.80M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 224.11M$ 191.29M$ -116.54M$ 84.47M$ 6.14M
Net Income From Continuing And Discontinued Operation
$ -217.44M$ -198.13M$ -121.82M$ -165.37M$ -3.41M
Normalized Income
$ -200.18M$ -171.69M-$ -164.98M$ -11.34M
Interest Expense
-----
EBIT
$ -226.31M$ -191.29M$ -122.77M$ -84.47M$ -932.00K
EBITDA
$ -210.66M$ -186.64M$ -111.00M$ -83.91M$ -889.00K
Currency in USD

Prime Medicine, Inc. Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis